Synthetic Biologics, Inc. (NYSEAMERICAN:SYN – Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $1.02. Synthetic Biologics shares last traded at $1.02, with a volume of 57,700 shares changing hands.
Synthetic Biologics Price Performance
The company has a market cap of $16.16 million, a PE ratio of -0.84 and a beta of 1.38.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Recommended Stories
- Five stocks we like better than Synthetic Biologics
- What Does Downgrade Mean in Investing?
- RXO Shares Surge Following New Acquisition Deal
- Compound Interest and Why It Matters When Investing
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What is a Bond Market Holiday? How to Invest and Trade
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.